FGL2 and gastrointestinal stromal tumor: We found in the randomized SSGXVIII trial patient population that patients with FGL2‐negative GIST had particularly poor RFS in the 1‐year adjuvant imatinib group but not in the 3‐year group, suggesting that patients with FGL2‐negative GIST might benefit most from the 3‐year duration of adjuvant imatinib.